Email This Content
Send an email to a colleague about this document. Non-subscribers may purchase the article.© Copyright 2010 WINDHOVER INFORMATION INC., All Rights Reserved
Windhover Information Inc. - Health Care Business Intelligence
Delivering essential analysis and insights to top health care executives, investment professionals, and industry consultants
By Pamela Taulbee, The Pink Sheet DAILY 10/1/2008
"The Pink Sheet" DAILY -- One compound that caught the eye of analysts and attendees at the American College of Rheumatology's scientific meeting in San Francisco last week was a Phase III monoclonal antibody Pfizer is investigating for treatment of pain, tanezumab.
100% Satisfaction Guarantee
If you are already a subscriber, please log in for complete access. 
Questions? Call (800) 332-2181
Click an article title to see a free preview.
Pfizer Discontinues Two Phase III Primary Care Projects, The Pink Sheet DAILY 2/24/2009
